DIVA Laboratories, Ltd. (TPEX:4153)
33.00
0.00 (0.00%)
Aug 18, 2026, 1:30 PM CST
DIVA Laboratories Revenue
DIVA Laboratories had revenue of 245.06M TWD in the quarter ending June 30, 2026, with 4.27% growth. This brings the company's revenue in the last twelve months to 894.67M, up 4.15% year-over-year. In the year 2025, DIVA Laboratories had annual revenue of 868.84M with 0.76% growth.
Revenue (ttm)
894.67M
Revenue Growth
+4.15%
P/S Ratio
2.16
Revenue / Employee
5.81M
Employees
154
Market Cap
1.94B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 868.84M | 6.52M | 0.76% |
| Dec 31, 2024 | 862.32M | -31.52M | -3.53% |
| Dec 31, 2023 | 893.84M | -55.36M | -5.83% |
| Dec 31, 2022 | 949.20M | 236.97M | 33.27% |
| Dec 31, 2021 | 712.23M | -24.69M | -3.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BIONET | 1.29B |
| Genetics Generation Advancement | 614.42M |
| Kim Forest Enterprise | 599.63M |
| Welgene Biotech | 398.92M |
| Sofiva Genomics | 379.21M |
| Pharmigene | 187.88M |
| Puriblood Medical | 80.54M |